# US 10,369,165 B2 · Composition containing active components of Dracocephalum moldavica L. against myocardial ischemia-reperfusion injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,165 B2
- Document ID: US10369165B2
- Status: Granted
- Kind: B2
- Application number: 15/531,763
- Filed: 2015-03-06
- Published: 2017-09-21
- Granted: 2019-08-06
- Earliest claimed: 2014-12-03
- Assignees: Nanjing Ruiying Runze Biopharmaceutical Technology Co., Inc.
- Applicants: Nanjing Ruiying Runze Biopharmaceutical Technology Co., Inc.
- Inventors: Jing Shang; Dongsheng Yu; Youqing Tian; Huali Wu; Lin Ding; Jun Liu
- Web page: https://patentgrep.com/patent/US10369165B2

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a composition containing active components of Dracocephalum moldavica L. against myocardial ischemia-reperfusion injury (MIRI). The composition consists of active components and a pharmaceutically acceptable carrier, wherein the active components comprise luteolin, kaempferol and luteolin-7-O-glucoside. Pharmacodynamic experiments show that these three components can be combined together to synergistically treat myocardial ischemia-reperfusion injury.

## Claims

### Claim 1

A method for treating myocardial ischemia-reperfusion injury comprising administering a pharmaceutical composition comprising luteolin, kaempferol, luteolin-7-O-glucoside and a pharmaceutically accepted carrier, wherein the molar ratio among luteolin, kaempferol and luteolin-7-O-glucoside is 0.7-2.2:2.1-4.1:0.6-2.4.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the molar ratio among luteolin, kaempferol and luteolin-7-O-glucoside is 1.1-1.6:2.8-3.5:1.0-1.7.

### Claim 3 (depends on 1)

The method according to claim 1, the pharmaceutical composition being selected from the group consisting of a tablet, granule, capsule, injection and aerosol.

### Claim 4

A method for treating myocardial ischemia-reperfusion injury comprising administering a pharmaceutical composition consisting of pharmaceutical active component and pharmaceutically accepted carrier, the pharmaceutical active components comprising luteolin, kaempferol, luteolin-7-O-glucoside, wherein the molar ratio among luteolin, kaempferol and luteolin-7-O-glucoside is 1.1-1.6:2.8-3.5:1.0-1.7.